Clarametyx Biosciences is building a transformative biologic platform for biofilm-associated disease. Our fundamentally new category of non-antibiotic, pro-stewardship therapies and vaccines enables innate immune response and first line antibiotic efficacy against persistent infections. Clarametyx is led by veteran sector-relevant management and scientific experts, and is CARB-X funded for its lead CMTX-101 therapeutic monoclonal antibody for up to approximately $14.3 million though Phase 1b.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):